Next Article in Journal
Humoral Immunity and Antibody Responses against Diphtheria, Tetanus, and Pneumococcus after Immune Effector Cell Therapies: A Prospective Study
Next Article in Special Issue
Estimates of Potential Demand for Measles and Rubella Microarray Patches
Previous Article in Journal
Adjuvant Use of the Invariant-Natural-Killer-T-Cell Agonist α-Galactosylceramide Leads to Vaccine-Associated Enhanced Respiratory Disease in Influenza-Vaccinated Pigs
Previous Article in Special Issue
On the Path to Measles and Rubella Elimination Following Rubella-Containing Vaccine Introduction, 2000–2023, Namibia
 
 
Article

Article Versions Notes

Vaccines 2024, 12(9), 1069; https://doi.org/10.3390/vaccines12091069
Action Date Notes Link
article pdf uploaded. 18 September 2024 17:17 CEST Version of Record https://www.mdpi.com/2076-393X/12/9/1069/pdf-vor
article supplementary file uploaded. 18 September 2024 17:17 CEST - https://www.mdpi.com/2076-393X/12/9/1069#supplementary
article xml file uploaded 19 September 2024 06:50 CEST Original file -
article xml uploaded. 19 September 2024 06:50 CEST Update https://www.mdpi.com/2076-393X/12/9/1069/xml
article pdf uploaded. 19 September 2024 06:50 CEST Updated version of record https://www.mdpi.com/2076-393X/12/9/1069/pdf
article html file updated 19 September 2024 06:51 CEST Original file https://www.mdpi.com/2076-393X/12/9/1069/html
Back to TopTop